Health Advice for Children Traveling Internationally

Published on 27/03/2015 by admin

Filed under Pediatrics

Last modified 27/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1083 times

Chapter 168 Health Advice for Children Traveling Internationally

The health risks and pretravel requirements for children traveling internationally, particularly those <2 yr of age, differ from those for adults. In the USA, recommendations and vaccine requirements for travel to different countries are provided by the Centers for Disease Control and Prevention (CDC) and are available online at www.cdc.gov/travel/content/vaccinations.aspx.

General Travel Preparation

Parents of traveling children should seek medical consultation ≥4-6 wk before departure to obtain a realistic assessment of health risks, a schedule of vaccinations and list of medications, and instructions on dealing with disease during travel.

Underlying Medical Illness

Parents of traveling children should be asked whether the child has any current health problems or has had any problems in the past that have required medical evaluation or medication. Parents of children with medical conditions should take with them a brief medical summary and a sufficient supply of prescription medications for their children, with bottles that are clearly identified. For children requiring care by specialists, an international directory for that specialty can be consulted. A directory of physicians worldwide who speak English and who have met certain qualifications is available from the International Association for Medical Assistance to Travelers (www.iamat.org/index.cfm). If medical care is needed urgently when abroad, sources of information include the American embassy or consulate, hotel managers, travel agents catering to foreign tourists, and missionary hospitals.

Children with chronic cardiopulmonary disease, diabetes, allergies, and gastrointestinal (GI) problems, especially diarrhea associated with malabsorption or inflammatory bowel disease, are at particular risk for health problems when traveling. Children with severe food allergies should take several epinephrine autoinjectors with them. Patients with type 1 diabetes or hemophilia should carry an adequate supply of sterile needles, syringes, and disinfectant swabs. Special arrangements should be made for patients with bleeding disorders, those on anticoagulation therapy, and those who require hemodialysis. Biologic products such as clotting factor concentrates or immune globulin should be avoided if they are manufactured abroad. A travel health kit consisting of prescription medications and nonprescription items such as acetaminophen, an antihistamine, oral rehydration solution packets, antibiotic ointment, bandages, insect repellent, and sunscreen is highly recommended for all children.

Infectious Disease Precautions

Infectious disease risks to traveling children can generally be divided into four categories: foodborne infection, insect-borne infection, infection from contact with infected persons or through needle exposure, and infections from infected animals or the environment.

Insect-Borne Infections

Insect-borne infections for which traveling children are at risk include malaria, yellow fever, dengue, Japanese encephalitis, filariasis, trypanosomiasis, and onchocerciasis, depending on the area of travel. Malaria, yellow fever, Japanese encephalitis, and filariasis are typically caused by night-biting mosquitoes, whereas dengue is usually caused by day-biting mosquitoes.

Exposure to insect bites can be avoided by restricting high-risk activities, staying indoors in a screened and protected area from dusk to dawn, wearing appropriate attire, and using insect repellents containing permethrin or N,N-diethyl-m-toluamide (DEET). Rare instances of toxic encephalopathy have been reported in young children with exposure to high concentrations of DEET, but use of repellent with no more than 40% DEET and avoidance of repeated applications as well as avoiding application to mucous membranes minimize the risk of this complication. Concentrations of 25-35% DEET, to be applied every 4-6 hours as needed, are recommended for children, although longer-acting DEET products are available.

For infants, the parent should apply the repellant to the parent’s hands and then transfer it to the infant, avoiding the infant’s hands and face. Immobile young infants can also be protected by a microenvironment: chemically treated netting placed over car seats, strollers, or carriers. The American Academy of Pediatrics (AAP) recommends avoiding the use of DEET in infants <2 mo of age, given increased skin permeability.

Spraying clothing with permethrin, a synthetic pyrethroid, is a safe and effective method of reducing insect bites in children. Permethrin-sprayed clothes remain effective for ≥2 wk, even with laundering. Bed nets, particularly permethrin-impregnated bed nets, also decrease the risk of insect bites, and their use is highly recommended.

Immunizations

Parents should allow 4-6 wk before departure for optimal administration of vaccines to their children, because some immunizations require repeated doses for full protection and some vaccines and medications require either simultaneous or staggered dosing for optimal efficacy. Live-attenuated viral vaccines should be administered concurrently or ≥30 days apart to minimize immunologic interference. Intramuscular immunoglobulin (IG) interferes with the immune response to measles immunization and possibly to varicella immunization. If a child requires measles or varicella immunization, the vaccines should be given either 2 wk before or 3 mo after IG administration (longer with higher doses of intravenous IG). IG does not interfere with the immune response to oral typhoid, poliovirus, or yellow fever vaccines.

Vaccine products produced in eggs (yellow fever, influenza) may be associated with hypersensitivity responses including anaphylaxis in persons with known severe egg sensitivity. Screening by inquiring about adverse effects when eating eggs is a reasonable way to identify those at risk for anaphylaxis from receiving influenza or yellow fever vaccines. Although measles and mumps vaccines are produced in chick embryo cell cultures, children with egg allergy are at very low risk for anaphylaxis with these vaccines. Most hypersensitivity reactions to measles-containing vaccines have been attributed to trace amounts of gelatin or neomycin.

In general, live-virus vaccines (measles, varicella, live-attenuated influenza) and live bacterial vaccines (bacille Calmette-Guérin [BCG], oral typhoid) are contraindicated in immunocompromised persons. However, HIV-infected children who are not severely immunocompromised should receive measles and varicella vaccines (see Table 165-6). Asymptomatic HIV-infected children may also be vaccinated against yellow fever if the risk is significant, but children with symptomatic HIV infection should not receive yellow fever vaccine. Inactivated vaccines and toxoids are not contraindicated in immunocompromised children but may be associated with diminished immune responses.

Routine Childhood Vaccines

All children who travel should be immunized according to the routine childhood immunization schedule with all vaccines appropriate for their age (Chapter 165). The immunization schedule can be accelerated to maximize protection for traveling children, especially for unvaccinated or incompletely vaccinated children (see Fig. 165-4).

Diphtheria, Tetanus, and Pertussis

Diphtheria is endemic in many developing countries. After the disintegration of the Soviet Union in 1991, diphtheria re-emerged in the new independent states, highlighting the potential for new outbreaks under the right circumstances. Tetanus is a major cause of worldwide neonatal mortality and is most prevalent in tropical countries. Pertussis is common in developing countries and in some developed nations where pertussis immunization is less widespread than in the USA because of earlier concerns about the pertussis vaccine’s adverse effects. The incidence of pertussis also appears to be increasing in the USA with concern of waning immunity in adolescents and adults. Children traveling internationally should be up to date on diphtheria and tetanus toxoids and acellular pertussis (DTaP) immunization with completion of 5 doses by 4-6 yr of age. A single dose of an adolescent preparation of tetanus and diphtheria toxoids and acellular pertussis (TdaP) vaccine is recommended at 11-12 yr of age for those who have completed the recommended diphtheria, tetanus toxoids, and pertussis (DTP)/DTaP series and have not received a tetanus-diphtheria (Td) booster dose. Adolescents 13-18 yr of age and adults who have completed the DTP/DTaP series, have never received Tdap, and in whom it has been 5 yr or more since their last Td booster dose also should receive a single dose of TdaP.

Infants and children <7 yr old who have not completed the series may be immunized using an accelerated schedule in preparation for international travel (see Fig. 165-4). There is some protection after 2 doses 4 wk apart, but there is little benefit with only 1 dose.

Haemophilus Influenzae Type B

H. influenzae type b remains the leading cause of meningitis in children 6 mo to 3 yr of age in many developing countries. Before they travel, all unimmunized children <60 mo of age and all children with chronic illness at risk for H. influenzae type b infections should be vaccinated (Chapter 165). If a child <15 mo is unvaccinated, ≥2 doses 4 wk apart starting no younger than 6 wk of age should be given before travel. Between 15 and 59 mo, 1 dose should be given. Unvaccinated children >59 mo of age do not need vaccination unless they are at risk due to an immunosuppressive condition.

Measles, Mumps, and Rubella

Measles is still endemic in many developing countries and in some industrialized nations. Measles vaccine, preferably in combination with mumps and rubella vaccines (MMR), should be given to all children at 12-15 mo of age and at 4-6 yr of age, unless there is a contraindication (Chapter 165). In children traveling internationally, the second vaccination can be given as soon as 4 wk after the first. In the accelerated schedule, the first MMR vaccination can be given to children as young as 6 mo of age, but if the vaccine is given earlier than 12 mo of age, the child should be considered unvaccinated and given 2 additional doses ≥4 wk apart after 12 mo of age (see Fig. 165-4). Infants <6 mo of age are protected by maternal antibodies. HIV-infected children who travel abroad should be vaccinated unless they are severely immunocompromised (Chapter 268), because measles in HIV-infected children can be a devastating illness.

Pneumococcus

Streptococcus pneumoniae is the leading cause of bacterial pneumonia and among the leading causes of bacteremia and bacterial meningitis in children in developing and industrialized nations. Immunization against S. pneumoniae with a protein-conjugated pneumococcal vaccine is now part of routine childhood immunization in the USA. Unimmunized children should be immunized if they are at high risk, such as children with sickle cell disease, asplenia, HIV infection, congenital immunodeficiency, nephrotic syndrome, or chronic cardiac or pulmonary disease and those on immunosuppressive medication (Chapter 165). The Advisory Committee on Immunization Practices (ACIP) recommends that these children receive both the conjugate pneumococcal vaccine and the 23-valent polysaccharide vaccine ≥8 wk after the last conjugate vaccine dose. The ACIP also recommends that vaccination with conjugate pneumococcal vaccine be considered in all healthy unimmunized children 24-59 mo of age with 1 dose; conjugate pneumococcal vaccination of unimmunized children in this age group traveling internationally should be strongly considered for unvaccinated children between 6 wk and 12 mo of age should receive 2-3 doses of conjugate pneumococcal vaccine (depending on the age when starting the series) ≥4 wk apart with a booster at age 12-15 mo. For unvaccinated children ages 12-23 mo, 2 doses should be given ≥8 wk apart.

Poliomyelitis

Poliomyelitis was eradicated from the Western hemisphere in 1991 but remains endemic in several developing countries, and the 2004 epidemic in Nigeria underscored the importance of vaccination for preventing this disease. The poliovirus vaccination schedule in the USA is now a 4-dose, all-inactivated poliovirus (IPV) regimen (Chapter 165). Oral poliovirus vaccine (OPV) is no longer available in the USA. Unvaccinated adults who are at increased risk for exposure to poliovirus and who cannot complete the recommended IPV regimen (0, 1-2, and 6-12 mo) should receive 3 doses of IPV given ≥4 wk apart. For an accelerated dosing schedule for children, see Figure 165-4. Length of immunity conferred by IPV immunization is not known; a single booster dose of IPV is recommended for fully vaccinated adults traveling to endemic areas. Proof of vaccination is required to enter Saudi Arabia for the Hajj.

Rotavirus

Buy Membership for Pediatrics Category to continue reading. Learn more here